Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Peer-Assisted Telemedicine for Hepatitis C in People Who Use Drugs: A Randomized Controlled Trial.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04798521 (Oregon HIV/Hepatitis and Opioid Prevention and Engagement), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study: Tele-HCV Treatment Trial
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Synchronous Telemedicine Versus In-Person Care in Hepatitis C Treatment: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- Peer-assisted telemedicine for hepatitis C intervention in people experiencing housing instability.Harm reduction journal · 2026Trial
- Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study.Addiction science & clinical practice · 2025Trial
- Harm Reduction in Peer-Assisted Telemedicine for Hepatitis C: Secondary Outcomes of a Randomized Controlled Trial.Viruses · 2024Trial
- "She Was Real About It and Made Me Feel Life Is Important": Patient Perspectives on Peers' Role in Peer-Assisted Telemedicine Hepatitis C Treatment for People Who Use Drugs in Rural Communities.Journal of addiction medicineTrial
- A Framework for Emergency Department-Integrated Hepatitis C Test-and-Treat in the United States.Journal of viral hepatitis · 2026Review
- Low-Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire.Journal of viral hepatitis · 2026Article
- Hepatitis C care cascade using direct-acting antivirals in rural new York State from 2013 to 2023: a retrospective observational study.BMC infectious diseases · 2026Observational
- Rapid hepatitis C test and treat with peer support at opioid treatment programs (RAPID HCV): a hybrid effectiveness-implementation type 1 randomized control trial.Lancet regional health. Americas · 2026Article
- What's Hot This Year in ID Clinical Science 2025.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Cost-Effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United States.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Mobile Interventions and Telemedicine for Hepatitis C Elimination.JAMA network open · 2026Article
- Rationale, design, and methodology of a randomized controlled trial evaluating the impact of peer-enhanced care coordination on linkage to HCV care among formerly incarcerated individuals.Contemporary clinical trials · 2025Article
- Long-Term Benefits Following Hepatitis C Cure Through Facilitated Telemedicine; Experiences of People With Opioid use Disorder Five Years After Achieving a Sustained Virological Response.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Hepatitis C Treatment Initiation During Hospitalization for People Who Use Drugs: A Narrative Review of the Literature.Open forum infectious diseases · 2025Review
- Community engagement and chronic viral hepatitis public health interventions: a systematic review, meta-analysis, and complementary crowdsourcing open call.EClinicalMedicine · 2025Article
- Approaches to Offering Hepatitis C Treatment at Syringe Services Programs in the United States: A Scoping Review.Open forum infectious diseases · 2025Review
- Peer-Assisted Telemedicine for Hepatitis C (PATHS): Process evaluation results from a State Opioid Response-funded program.Journal of substance use and addiction treatment · 2024Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
backgroundHepatitis C virus (HCV) elimination requires treating people who use drugs (PWUD), yet <10% of PWUD in the United States access HCV treatment; access is especially limited in rural communities.
methodsWe randomized PWUD with HCV viremia and past 90-day injection drug or nonprescribed opioid use in 7 rural Oregon counties to peer-assisted telemedicine HCV treatment (TeleHCV) versus peer-assisted referral to local providers (enhanced usual care [EUC]). Peers supported screening and pretreatment laboratory evaluation for all participants and facilitated telemedicine visits, medication delivery, and adherence for TeleHCV participants. Generalized linear models estimated group differences in HCV viral clearance (primary outcome) and HCV treatment initiation and completion (secondary outcomes).
resultsOf the 203 randomized participants (100 TeleHCV, 103 EUC), most were male (62%), White (88%), with recent houselessness (70%), and used methamphetamines (88%) or fentanyl/heroin (58%) in the past 30 days. Eighty-five of 100 TeleHCV participants (85%) initiated treatment versus 13 of 103 (12%) EUC participants (relative risk [RR], 6.7 [95% confidence interval {CI}, 4.0-11.3]; P < .001). Sixty-three of 100 (63%) TeleHCV participants versus 16 of 103 (16%) EUC participants achieved viral clearance 12 weeks after anticipated treatment completion date (RR, 4.1 [95% CI: 2.5-6.5]; P < .001).
conclusionsThe Peer TeleHCV treatment model substantially increased HCV treatment initiation and viral clearance compared to EUC. Replication in other rural and low-resource settings could further World Health Organization HCV elimination goals by expanding and decentralizing treatment access for PWUD. Clinical Trials Registration. NCT04798521.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.